GlobeNewswire Inc | Nov 18, 2021 07:00AM EST

November 18, 2021

TEAMMATE Study to Assess Impact in 4,000 Patients Across100 Transplant Centers

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the enrollment of the first patients in what will be the largest ever digital study measuring the impact of AlloCare, a tech-enabled mobile health app, on organ transplant patient outcomes.

The TEAMMATE (Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient) study will enroll 4,000 patients from more than 100 transplant centers nationwide as part of a prospective, randomized, controlled, multicenter study spanning kidney, heart, lung, and liver transplantation. Half of the participants will be enrolled in the study arm and half in the control arm. The study arm will have patients trained for regular use of the AlloCare mobile health app. The control arm will maintain the centers standard of care. The primary endpoint will be 90-day readmission rates. The secondary endpoints will include medication adherence, blood pressure management, organ rejection at 3, 6, and 12 months, and patient satisfaction levels.

AlloCare is a patient management app that helps transplant recipients precisely manage their medications, schedule their lab work, track their blood pressure and other vital metrics, view their AlloSure and other test results, and connect with other transplant recipients. AlloSure is a non-invasive transplant diagnostic tool that measures donor-derived cell-free DNA (dd-cfDNA) levels released into the blood stream to indicate potential, post-transplant allograft injury.

AlloCare is a comprehensive, tech-enabled mobile health app created specifically for transplant patients, and thats critically important because precise management of immunosuppressive medications is the most important factor in lowering the risk of organ rejection, said Dr. Sham Dholakia, Chief Medical Officer at CareDx. This study will test the hypothesis that using AlloCare will empower solid organ transplant patients and their caregivers to achieve better adherence and, ultimately, better outcomes.

Effective post-transplant care requires that recipients adhere precisely to their medication schedule, and this large-scale study will determine whether we can drive improvements in clinical outcomes by deploying a comprehensive mobile health app created specifically for transplantation, said Dr. Malay Shah, Associate Professor of Surgery at the University of Kentucky. Unfortunately, medication non-adherence is far too common, and I look forward to seeing how AlloCare can not only help improve patient adherence but health outcomes as well.

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the patient enrollment in TEAMMATE study (the Study), the Studys measurement of the impact of using AlloCare, and the potential benefits and results that may be achieved through the Study and AlloCare. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that the CareDx does not realize the expected benefits of the Study or AlloCare; risks that CareDx fails to enroll 4,000 patients in the Study or conduct the Study as planned; risks that the Study fails to demonstrate that the use of AlloCare may achieve better outcomes; general economic and market factors; and other risks discussed in CareDxs filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by CareDx with the SEC on February 24, 2021 and other reports that CareDx has filed with the SEC. Any of these may cause CareDxs actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDxs forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

ContactsSasha KingChief Marketing Officer(415) 287-2393sking@CareDx.com

Investor RelationsIan Cooney(415) 722-4563investor@CareDx.com